Medicenna to Participate at The H.C. Wainwright 25th Annual Global Investment Conference
September 06 2023 - 7:00AM
Medicenna Therapeutics Corp. (“Medicenna” or “the Company”)
(NASDAQ: MDNA TSX: MDNA), a clinical-stage immunotherapy company
focused on the development of novel Superkines, announced that
Dr. Fahar Merchant, President and CEO is scheduled to
participate in a fireside chat at the H.C. Wainwright 25th Annual
Global Investment Conference on September 13, 2023, at 2:30 PM ET.
The fireside chat will be live-streamed and
available on the H.C. Wainwright Conference Platform for 30 days.
Please contact your H.C. Wainwright representative for more
information.
About MedicennaMedicenna is a
clinical-stage immunotherapy company focused on the development of
novel, highly selective versions of IL-2, IL-4 and IL-13 Superkines
and first in class class-empowered superkines. Medicenna’s
long-acting IL-2 Superkine, MDNA11, is a next-generation IL-2 with
superior CD122 (IL-2 receptor beta) binding without CD25 (IL-2
receptor alpha) affinity thereby preferentially stimulating
cancer-killing effector T cells and NK cells. Medicenna’s IL-4
Empowered Superkine, bizaxofusp (formerly MDNA55), has been studied
in 5 clinical trials including a Phase 2b trial for recurrent GBM,
the most common and uniformly fatal form of brain cancer.
Bizaxofusp has obtained FastTrack and Orphan Drug status from the
FDA and FDA/EMA, respectively. Medicenna’s early-stage BiSKITs™
program, (Bifunctional
SuperKine
ImmunoTherapies) is designed to
enhance the ability of Superkines to treat immunologically “cold”
tumors.
Further Information & Investor Contact:
For further information about the Company please contact:
Delphine Davan Vice President, Investor Relations and Corporate
Communications, Phone: +1 (647) 474-2641ddavan@medicenna.com
Medicenna Therapeutics (NASDAQ:MDNA)
Historical Stock Chart
From Apr 2024 to May 2024
Medicenna Therapeutics (NASDAQ:MDNA)
Historical Stock Chart
From May 2023 to May 2024